LI
SRPT icon

LRI Investments’s Sarepta Therapeutics SRPT Stock Holding History

LRI Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18 Buy
+1
New +$19 ﹤0.01% 1943
2024
Q2 		– Sell
-38
Closed -$4.92K – 1141
2024
Q1 		$4.92K Buy
+38
New +$4.66K ﹤0.01% 630

Other funds holding SRPT

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $5.7B AUM 35.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
YCM
Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return
COPPSERS
Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

LRI Investments's SRPT Position: Q2 2026 in Review

LRI Investments opened a new position in Sarepta Therapeutics (SRPT) in Q2 2026: 1 share worth $18. The stake represents ﹤0.01% of the portfolio and ranks #1943 among its holdings. This is a return to the name: LRI Investments previously reported a position in SRPT as recently as Q1 2024.

LRI Investments first reported a position in SRPT in Q1 2024 and has held it in 2 quarters since. The position peaked at $4.92K in Q1 2024. 32 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • LRI Investments held 1 share of Sarepta Therapeutics worth $18 as of Q2 2026.
  • Sarepta Therapeutics was a new LRI Investments position in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1943 holding.
  • LRI Investments first reported a position in Sarepta Therapeutics in Q1 2024 and has held it in 2 quarters since.
  • LRI Investments's Sarepta Therapeutics position peaked at $4.92K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.